Patents by Inventor Ella Magal

Ella Magal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for preventing and treating hearing loss using sensorineurotrophic compounds
    Publication number: 20040186098
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering sensorineurotrophic compounds described below. The invention relates more specifically to methods for treating sensorineural hearing loss as well as vestibular disorders and tinnitus.
    Type: Application
    Filed: March 29, 2004
    Publication date: September 23, 2004
    Applicant: Amgen Inc.
    Inventor: Ella Magal
  • Eck receptor ligands
    Patent number: 6479250
    Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: November 12, 2002
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
  • Method for preventing and treating hearing loss using a neurturin protein product
    Patent number: 6274554
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering a neurturin neurotrophic factor protein product. The invention relates more specifically to methods for treating sensorineural hearing loss.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: August 14, 2001
    Assignee: Amgen Inc.
    Inventors: Ella Magal, John M. Delaney
  • Eck receptor ligands
    Patent number: 6087167
    Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: July 11, 2000
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
  • Method for preventing and treating hearing loss using a neuturin protein product
    Patent number: 6043221
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering a neurturin neurotrophic factor protein product. The invention relates more specifically to methods for treating sensorineural hearing loss.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: March 28, 2000
    Assignee: Amgen Inc.
    Inventors: Ella Magal, John M. Delaney
  • Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
    Patent number: 5929041
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear (and vestibular) hair cells and spiral ganglion neurons (as well as vestibular neurons--Carpa's neurons) by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates more specifically to methods for treating sensorineural hearing loss and vestibular disorders.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: July 27, 1999
    Assignee: Amgen Inc.
    Inventor: Ella Magal
  • Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
    Patent number: 5837681
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates more specifically to methods for treating sensorineural hearing loss.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: November 17, 1998
    Assignee: Amgen Inc.
    Inventor: Ella Magal
  • Eck receptor ligands
    Patent number: 5824303
    Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: October 20, 1998
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker